Hansa Biopharma AB Share Price Nasdaq Stockholm
Equities
SE0002148817
Biotechnology & Medical Research
Sales 2024 * | 239M 21.87M 1.75B | Sales 2025 * | 343M 31.32M 2.51B | Capitalization | 1.5B 137M 11B |
---|---|---|---|---|---|
Net income 2024 * | -735M -67.18M -5.38B | Net income 2025 * | -712M -65.08M -5.21B | EV / Sales 2024 * | 8.27 x |
Net Debt 2024 * | 474M 43.33M 3.47B | Net Debt 2025 * | 733M 67.04M 5.37B | EV / Sales 2025 * | 6.53 x |
P/E ratio 2024 * |
-2.37
x | P/E ratio 2025 * |
-2.81
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 19/03/18 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 11-30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 28/05/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 28/05/18 | |
Peter Nicklin
CHM | Chairman | 61 | 29/06/22 |
Mats Blom
BRD | Director/Board Member | 59 | 21/05/19 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |